The Cost-effectiveness Analysis Of Three Treatments Schemes On Type-2 Diabetes

Objective:To evaluate the cost effectiveness of three treatment schemes on type 2 diabetes mellitus.Methods:157 patients of type 2 diabetes mellitus were enrolled into a retrospective. Three treatment strategies (Group A:Glimepiride + Metformin; Group B: Glimepiride + Acarbose; Group C:Glimepiride+Rosiglitazone) were estimated by the cost-effectiveness analysis accounding to the content of blood glucose and HbA1c.Results:After treatment for 12 weeks, the effective rate of three schemes were 86.3%, 88.2%,96.4%, respectively. Scheme C was better than the other two. The total costs were CNY 445.5,780.1,1340.0, respectively. Fasting blood glucose level of three schemes were of significant differences(P<0.05). The cost-effective ratio were 15.7, 24.5,33.7 to blood sugar level, and 98.6,154.2,223.7 to HbAlc, respectively. Sensitivity analysis revealed that the results were not sensitive to changes in the drug cost.Conclusions:Blood sugar level can be controlled to an ideal level through the three treatment schemes; Scheme A is better for decreasing blood glucose. Scheme C is more effective, but more expensive.